Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
Tan CR, Usmani S, Derkach A, de Meneze Silva Corraes A, Parrondo R, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O, Hajek R, Mihalyova J, Htut M, Janakiram M, Visram A, Kastritis E, Dimopoulos MA, Mart?nez-L?pez J, Nagarajan C, Bal S, Costa LJ, Einsele H, Steinbrunn T, Waldschmidt JM, Riedhammer C, Banerjee R, Chng WJ, Tso A, Lin Y, Martin T, Mian H. Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis. Blood Adv. 2026 May 12; 10(9):2937-2946.
-
Hamadeh IS, Merz M, Derkach A, Modelevsky L, Lesokhin AM, Mailankody S, Hultcrantz ML, Tan CR, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Hashmi H, Maura F, Firestone RS, Wang AX, Amin A, Patel D, Scordo M, Shah GL, Landau HJ, Giralt S, Usmani SZ, Korde N. Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies. Clin Lymphoma Myeloma Leuk. 2026 Jun; 26(6):e802-e810.
-
Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodr?guez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosi?ol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. N Engl J Med. 2026 Jan 01; 394(1):51-61.
-
Hamadeh IS, Modelevsky L, Chan A, Mitchell A, Firestone RS, Wang AX, Shekarkhand T, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Hashmi H, Patel D, Shah GL, Scordo M, Landau HJ, Giralt S, Usmani SZ, Tan CR. Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses. JCO Oncol Pract. 2026 Jun; 22(6):1105-1111.
-
Adegbite B, Tan CR, Shekarkhand T, Firestone RS, Jurgens EM, Miller K, Lesokhin AM, Shah GL, Korde N, Rajeeve S, Landau HJ, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz M, Hamadeh IS, Derkach A, Nemirovsky D, Giralt SA, Mailankody S, Usmani SZ, Hashmi H. Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma. Blood Adv. 2025 Aug 12; 9(15):4016-4022.
-
Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM, Chhabra S, Parrondo R, Ailawadhi S, Fotiou D, Dimopoulos MA, Yong K, Mactier C, Lau C, Corona M, Marin AJS, Mian H, Durie BG, Usmani SZ, Martin TG, Lin Y. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J. 2025 Apr 03; 15(1):53.
-
Gerber WK, Xie Y, Patel SA. Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors. JCO Precis Oncol. 2025 Mar; 9:e2400753.
-
Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona RI, Girgis S, Miao X, Uhlar CM, Chastain K, Garfall AL. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024 Dec 05; 144(23):2375-2388.
-
Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, Lau O, Calara-Nielsen K, Davis C, Patel J, Banerjee A, Stephenson T, Uhlar C, Kobos R, Goldberg J, Pei L, Trancucci D, Girgis S, Wang Lin SX, Wu LS, Moreau P, Usmani SZ, Bahlis NJ, van de Donk NWCJ, Verona RI. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024 08 08; 144(6):615-628.
-
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah U, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Usmani SZ, Chung DJ. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood. 2024 07 25; 144(4):402-407.